Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
The price of Akero Therapeutics Inc (NASDAQ: AKRO) closed at $40.99 in the last session, up 3.48% from day before closing price of $39.61. In other words, the price has increased by $3.48 from its previous closing price. On the day, 1.87 million shares were traded. AKRO stock price reached its highest trading level at $41.44 during the session, while it also had its lowest trading level at $39.18.
Ratios:
We take a closer look at AKRO’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 19.38 and its Current Ratio is at 19.38. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.05.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, BofA Securities on January 30, 2025, Upgraded its rating to Buy and sets its target price to $63 from $35 previously.
On January 27, 2025, H.C. Wainwright reiterated its Buy rating and also lowered its target price recommendation from $50 to $72.
On November 18, 2024, Citigroup started tracking the stock assigning a Buy rating and target price of $65.Citigroup initiated its Buy rating on November 18, 2024, with a $65 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Apr 15 ’25 when Yale Catriona sold 9,073 shares for $37.91 per share. The transaction valued at 343,962 led to the insider holds 95,034 shares of the business.
Cheng Andrew sold 30,000 shares of AKRO for $1,056,780 on Apr 10 ’25. The President and CEO now owns 624,324 shares after completing the transaction at $35.23 per share. On Apr 07 ’25, another insider, Rolph Timothy, who serves as the Chief Scientific Officer of the company, sold 6,250 shares for $35.88 each. As a result, the insider received 224,262 and left with 169,721 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AKRO now has a Market Capitalization of 3263627776 and an Enterprise Value of 2556668160.
Stock Price History:
The Beta on a monthly basis for AKRO is -0.08, which has changed by 1.0764945 over the last 52 weeks, in comparison to a change of 0.07545352 over the same period for the S&P500. Over the past 52 weeks, AKRO has reached a high of $58.40, while it has fallen to a 52-week low of $17.86. The 50-Day Moving Average of the stock is -5.15%, while the 200-Day Moving Average is calculated to be 22.70%.
Shares Statistics:
According to the various share statistics, AKRO traded on average about 1.43M shares per day over the past 3-months and 999690 shares per day over the past 10 days. A total of 72.38M shares are outstanding, with a floating share count of 70.71M. Insiders hold about 11.19% of the company’s shares, while institutions hold 87.36% stake in the company. Shares short for AKRO as of 1743379200 were 5487243 with a Short Ratio of 3.83, compared to 1740700800 on 5052816. Therefore, it implies a Short% of Shares Outstanding of 5487243 and a Short% of Float of 7.0700005.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
